Effects of extended-release 7-nitroindazole gel formulation treatment on the behavior of Shank3 mouse model of autism

Keyphrases

• Extended Release 100%
• Autism Mouse Model 100%
• SHANK3 100%
• Gel Formulation 100%
• 7-nitroindazole 100%
• Autism Spectrum Disorder 71%
• Ricinoleic Acid 42%
• Sebacic Acid 42%
• Acid Gel 42%
• Mutant Mice 28%
• Anxiety-like Behavior 28%
• In(III) 14%
• Nitrosative Stress 14%
• Rational Design 14%
• Intraperitoneal Injection 14%
• Social Interaction 14%
• Behavioral Tests 14%
• Tyrosine 14%
• Neurodevelopmental Disorders 14%
• Protein S-nitrosylation 14%
• Therapeutic Effect 14%
• Repetitive Behavior 14%
• Behavioral Deficits 14%
• Plasma Parameters 14%
• Clinical Translation 14%
• CNTNAP2 14%
• Slow Release 14%
• Nitric Oxide Level 14%
• Drug System 14%
• Neuronal Nitric Oxide Synthase Inhibitor 14%
• Memory Interaction 14%
• New Preparations 14%
• Social Interaction Anxiety 14%
• Mutant Mouse Models 14%
• Social Interaction Behavior 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse Model 100%
• Autism 100%
• 7 Nitroindazole 100%
• Mouse Mutant 60%
• Ricinoleic Acid 60%
• Sebacic Acid 60%
• Disease 20%
• Combination Therapy 20%
• Nitric Oxide 20%
• Intraperitoneal Injection 20%
• Compulsion 20%
• Therapeutic Effect 20%
• Protein S 20%
• Nitric Oxide Synthase Inhibitor 20%
• Neuronal Nitric Oxide Synthase 20%
• 3 Nitrotyrosine 20%
• Drug System 20%

Neuroscience

• Behavior (Neuroscience) 100%
• Pervasive Developmental Disorder 100%
• 7-Nitroindazole 100%
• Ricinoleic Acid 60%
• Social Interaction 40%
• Blood Plasma 40%
• Nitrosative Stress 20%
• Nitric Oxide 20%
• Intraperitoneal Injection 20%
• Behavioral Test 20%
• Neurodevelopmental Disorder 20%
• Protein S 20%
• Compulsive Behavior 20%
• Nitrotyrosine 20%
• Neuronal Nitric Oxide Synthase 20%